Repligen Corporation reports business developments as a global life sciences company focused on bioprocessing technologies and systems used in manufacturing biological drugs. Its updates center on Filtration and Fluid Management, Chromatography, Process Analytics and Proteins, serving biopharmaceutical drug developers, CDMOs and other life science customers.
Recurring announcements include quarterly and annual financial results, financial guidance, organic revenue measures, margin commentary, product and support infrastructure such as Repligen Training & Innovation Centers and OPUS pre-packed chromatography columns, investor conference participation, regional customer support initiatives and board or senior finance governance changes.
Repligen (NASDAQ:RGEN) will participate in the Jefferies Global Healthcare Conference in London on November 18, 2026, through an analyst-led discussion. President and CEO Olivier Loeillot will join the discussion at 2:00 p.m. GMT. A live webcast will be accessible through Repligen’s Investor Relations website, with a replay available for a limited period afterward.
Repligen (NASDAQ:RGEN) entered into agreements to issue $1.0 billion of convertible senior notes through private exchanges and cash subscriptions. The 0.25% notes due 2031 include approximately $541.4 million exchanged for approximately $456.8 million of 1.00% notes due 2028, plus approximately $458.6 million issued for cash.
The initial conversion price is approximately $226.37 per share, approximately 20% above the October 29, 2026 closing price. Repligen expects closing on or about November 6, 2026; approximately $143.2 million of 2028 notes will remain outstanding with unchanged terms. Estimated subscription gross proceeds are approximately $458.6 million before fees and expenses. Repligen plans to use approximately $120.0 million of net proceeds to repurchase shares at $188.64 each, with the remainder for working capital and general corporate purposes, including possible acquisitions or investments.
Repligen (RGEN) reported third-quarter revenue of $209.3 million, with year-over-year growth and a higher full-year revenue outlook following its BioLife acquisition. Revenue rose 11% as reported and 12.5% organically. A $41.242 million intangible asset impairment charge contributed to a GAAP operating loss of $29.5 million, versus $16.8 million profit. Diluted loss per share was $0.68, versus earnings of $0.26. Adjusted diluted earnings rose to $0.53 from $0.46.
Repligen completed the BioLife Solutions acquisition on October 6, 2026, adding a cell-therapy consumables platform. The company raised its 2026 revenue outlook to $844–$852 million, representing 14.5%–15.5% reported growth, and expects adjusted diluted earnings of $2.05–$2.09. Guidance includes BioLife from closing. Cash, cash equivalents and marketable securities totaled $863 million at September 30, versus $768 million at December 31, 2025.
Repligen (RGEN) will report its third quarter 2026 financial results before the market opens on October 27, 2026. A conference call and webcast at 8:00 a.m. ET that day will cover business updates and results for the three months ended September 30, 2026. The webcast and an archived replay will be available through the company's Investor Relations website.
Repligen (NASDAQ: RGEN) has completed its previously announced acquisition of BioLife Solutions, adding cell processing tools and services for cell therapies.
BioLife stockholders received $11.25 per share in cash and 0.1442 shares of Repligen common stock, with cash paid instead of fractional shares. BioLife's biopreservation media portfolio, led by CryoStor, supports 18 commercially approved therapies and the majority of U.S. commercially sponsored cell-based therapy trials.
Repligen expects the combination to broaden its cell therapy presence and connect BioLife's customer relationships with its global commercial reach, including Asia Pacific. The company intends to provide details on the transaction's expected impact on its 2026 financial outlook during its upcoming third-quarter earnings call.
Freshworks (FRSH) will replace BioLife Solutions (BLFS) in the S&P SmallCap 600 before trading opens on October 8, 2026. Freshworks will enter the index in the Information Technology sector, while BioLife Solutions will leave the Health Care sector. Repligen (RGEN), an S&P MidCap 400 constituent, is acquiring BioLife Solutions.
Repligen (NASDAQ:RGEN) will participate in the Wells Fargo 21st Annual Healthcare Conference in Boston, MA. President and CEO Olivier Loeillot and CFO Jason Garland are scheduled for an analyst-led discussion on September 9 at 1:30 p.m. ET.
A live webcast and limited-time replay of the presentation will be available through Repligen’s Investor Relations website. The company develops and commercializes bioprocessing technologies for biopharmaceutical developers and CDMOs worldwide.
Repligen (NASDAQ:RGEN) reported Q2 2026 revenue of $204 million, up 12% year-over-year as reported and 13% organically. GAAP income from operations was $14 million, flat year-over-year, while adjusted income from operations rose to $34 million from $22 million. GAAP diluted EPS was $0.09 versus $0.26, and adjusted diluted EPS increased to $0.54 from $0.37. GAAP gross margin was 53.9%, with adjusted operating margin improving to 16.7% from 12.0%. Cash, cash equivalents and marketable securities totaled $810 million at June 30, 2026.
For full-year 2026, Repligen now guides adjusted total revenue of $813–$835 million, implying 10–13% reported growth and 10.5–13.5% organic growth, adjusted operating margin of 15.7–16.0%, and adjusted diluted EPS of $2.03–$2.09. The company also announced a definitive agreement to acquire BioLife Solutions, intended to strengthen its cell therapy consumables platform.
Repligen (NASDAQ:RGEN) agreed to acquire BioLife Solutions (NASDAQ:BLFS) in a cash-and-stock deal valuing BioLife at an enterprise value of approximately $1.5 billion. BioLife stockholders will receive $11.25 in cash and 0.1442 Repligen shares per BioLife share, implying total consideration of $31.00 per share, a 24% premium to BioLife’s 90-day VWAP.
The mix is approximately 64% Repligen stock and 36% cash, funded with cash on hand. Repligen expects the transaction to be accretive to top-line growth, adjusted margins and adjusted EPS by at least $0.05 in year one and $0.25 in year two, with targeted cost synergies of at least $20 million in year one and $30 million in year two. Pro forma cash and equivalents are expected to exceed $300 million. Repligen also reported preliminary Q2 2026 revenue growth of 12% reported and 13% organic, while BioLife’s preliminary Q2 2026 revenue rose 21% year-over-year to $28.5 million. Closing is targeted for Q4 2026, subject to regulatory and BioLife stockholder approvals.
Repligen (NASDAQ:RGEN) will report its second quarter 2026 financial results on Tuesday, July 28, 2026. A press release will be issued before the market opens, followed by a conference call and webcast at 8:00 a.m. ET to discuss business updates and results for the quarter ended June 30, 2026.
The call can be accessed toll-free at (833) 461-5787 for U.S. callers and (585) 542-9983 for international participants, using meeting ID 768981187. A live and archived webcast will be available in the Investor Relations section of Repligen’s website.